2022 CNS Annual MeetingOctober 10-12 in San Francisco
Stop by and see us at Booth #509
RapidAI enables neurovascular and vascular clinical teams to push the boundaries of care, reducing time to treatment and improving patient outcomes. We empower physicians to make faster more accurate diagnostic, treatment and transfer decisions. We connect care teams for more streamlined and improved communication and coordination of the patient journey. We enable coordinators and administrators to optimize protocols and reduce costs.
Delivered via mobile device, desktop and PACS, the Rapid clinical platform leverages artificial intelligence (AI) to create enhanced, high-quality images from NCCT, CTA, CTP and MRI diffusion and perfusion data, helping physicians make expedient diagnoses and treatment and transfer decisions.
Workflow solutions help standardize disease-specific patient workflows and optimize care team coordination—including messaging and communication, new case notification, and Rapid results delivery—enabling team members to align and initiate workflow actions prior to or upon patient arrival and securely communicate throughout the patient journey.
Analytics reporting offers valuable insights on hospital protocols, patient outcomes, and effectiveness of Rapid product usage to increase efficiency and help standardize processes—within a single site or across an entire hospital network.
Created by clinicians for clinicians, RapidAI provides the most advanced, clinically proven software platform for acute and non-acute vascular and neurovascular conditions, to enable physicians to make faster, more accurate diagnostic and treatment decisions. The Rapid platform has been clinically validated in a number of worldwide studies producing results that have paved the way for a new standard of care for stroke patients that was endorsed by the American Heart Association guidelines in 2015. Our clinical team continues to remain actively involved in studies around the world working with hospitals to help shape the future of care.
The Rapid platform has been developed on a foundation of extensibility—allowing hospitals to easily implement one platform to address the needs of multiple departments for neurovascular and vascular conditions—including stroke, aneurysm, and pulmonary embolism. Through the seamless integration of advanced imaging using artificial intelligence and the delivery of results through workflow tools, we provide clinical decision and workflow support care teams need to quickly and effectively diagnose, triage, and treat patients. Hospitals that standardize on the Rapid platform will quickly benefit from single-vendor installation and support, the highest data security and compliance, and the operational and behavioral efficiencies gained from using a single platform.
The Rapid platform was designed on the principle of reducing time from the patient workflow. Fast delivery of advanced Rapid results on mobile or desktop devices enables physicians to make faster, more informed diagnosis and treatment decisions. Rapid workflow tools keep team members informed and help streamline and speed-up patient care coordination.
Our flexible platform works in any hospital environment including Emergency Departments, Trauma Centers, Acute Stroke Ready Hospitals, Primary Stroke Centers, and Comprehensive Stroke Centers. It’s an ideal solution for multi-site systems and referral networks that can benefit from the sharing of critical patient information and analytic reporting to help improve cross-hospital audit capabilities, workflow analysis, and healthcare economics.
RapidAI is committed to upholding the most rigorous information security standards. To this end, we continually invest in people, processes and technology to protect our platform and data. The Rapid platform has been developed using the National Institute of Standards and Technology (NIST) cybersecurity framework. It is also HIPAA compliant, GDPR compliant, ISO 13485, ISO 27001, and ISO 27701 certified.
Rapid U provides customers with the advanced training they need to be successful when using RapidAI products in their professional roles. The educational content and resources offered through Rapid U are tailored to suit the individual needs of each member of a stroke care team through a series of role-based learning paths. Each learning path, includes:
After the initial validation of an NIH-sponsored DEFUSE 2 study published in 2012 and extensively studied in 14 worldwide clinical trials, iSchemaView purchased the technology rights to the software that same year. Since then, adoption of the Rapid® platform has quickly grown.
In early 2019, iSchemaView received FDA clearance that allows physicians to use our imaging platform to select stroke patients likely to benefit from endovascular thrombectomy (clot removal.) We believe this advancement will benefit small community hospitals and the patients they serve.
“...RAPID is unparalleled in ease of implementation and use. RAPID elevates perfusion imaging in the management of acute ischemic stroke.”